59 related articles for article (PubMed ID: 17308921)
1. Cost-effectiveness analysis of human papillomavirus DNA testing and Pap smear for cervical cancer screening in a publicly financed health-care system.
Chow IH; Tang CH; You SL; Liao CH; Chu TY; Chen CJ; Chen CA; Pwu RF
Br J Cancer; 2010 Dec; 103(12):1773-82. PubMed ID: 21102588
[TBL] [Abstract][Full Text] [Related]
2. Cost of screening and treatment of cervical dyskaryosis in Germany.
Petry KU; Breugelmans JG; Bénard S; Lamure E; Littlewood KJ; Hillemanns P
Eur J Gynaecol Oncol; 2008; 29(4):345-9. PubMed ID: 18714567
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis for Pap smear screening and human papillomavirus DNA testing and vaccination.
Chen MK; Hung HF; Duffy S; Yen AM; Chen HH
J Eval Clin Pract; 2011 Dec; 17(6):1050-8. PubMed ID: 21679279
[TBL] [Abstract][Full Text] [Related]
4. Screening for cervical cancer with the human papillomavirus test in an area of central Italy with no previous active cytological screening programme.
Confortini M; Giorgi Rossi P; Barbarino P; Passarelli AM; Orzella L; Tufi MC
J Med Screen; 2010; 17(2):79-86. PubMed ID: 20660436
[TBL] [Abstract][Full Text] [Related]
5. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries.
Cuzick J; Arbyn M; Sankaranarayanan R; Tsu V; Ronco G; Mayrand MH; Dillner J; Meijer CJ
Vaccine; 2008 Aug; 26 Suppl 10():K29-41. PubMed ID: 18847555
[TBL] [Abstract][Full Text] [Related]
6. [Cervical cancer screening and associated treatment costs in France].
Bergeron C; Breugelmans JG; Bouée S; Lorans C; Bénard S; Rémy V
Gynecol Obstet Fertil; 2006 Nov; 34(11):1036-42. PubMed ID: 17070085
[TBL] [Abstract][Full Text] [Related]
7. Cervical cancer screening program integrating Pap smear and HPV DNA testing: a population-based study.
Chao A; Hsu KH; Lai CH; Huang HJ; Hsueh S; Lin SR; Jung SM; Chao FY; Huang SL; Huang CC; Yang JE; Chang TC
Int J Cancer; 2008 Jun; 122(12):2835-41. PubMed ID: 18338752
[TBL] [Abstract][Full Text] [Related]
8. [Role of cytological test for cervices to identify human papillomavirus in the screening program on serious cervical lesion].
Wang GP; Li RZ; Wu LN; Li J; Liu ZH; Wang C; Zhou YQ; Weng LM; Wu RF
Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Jun; 30(6):626-30. PubMed ID: 19957634
[TBL] [Abstract][Full Text] [Related]
9. Human papillomavirus testing with Pap triage for cervical cancer prevention in Canada: a cost-effectiveness analysis.
Kulasingam SL; Rajan R; St Pierre Y; Atwood CV; Myers ER; Franco EL
BMC Med; 2009 Nov; 7():69. PubMed ID: 19900264
[TBL] [Abstract][Full Text] [Related]
10. HPV triage testing or repeat Pap smear for the management of atypical squamous cells (ASCUS) on Pap smear: is there evidence of process utility?
Howard K; Salkeld G; McCaffery K; Irwig L
Health Econ; 2008 May; 17(5):593-605. PubMed ID: 17764095
[TBL] [Abstract][Full Text] [Related]
11. Improving the performance of reflex Human Papilloma Virus (HPV) testing in triaging women with atypical squamous cells of undetermined significance (ASCUS): A restrospective study in a tertiary hospital in United Arab Emirates (UAE).
Fakhreldin M; Elmasry K
Vaccine; 2016 Feb; 34(6):823-30. PubMed ID: 26747717
[TBL] [Abstract][Full Text] [Related]
12. Comparison of HPV test versus conventional and automation-assisted Pap screening as potential screening tools for preventing cervical cancer.
Nieminen P; Vuorma S; Viikki M; Hakama M; Anttila A
BJOG; 2004 Aug; 111(8):842-8. PubMed ID: 15270934
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of primarily human papillomavirus-based cervical cancer screening in settings with currently established Pap screening: a systematic review commissioned by the German Federal Ministry of Health.
Mühlberger N; Sroczynski G; Esteban E; Mittendorf T; Miksad RA; Siebert U
Int J Technol Assess Health Care; 2008; 24(2):184-92. PubMed ID: 18400122
[TBL] [Abstract][Full Text] [Related]
14. Economic evaluation of hybrid capture human papillomavirus testing in women with low-grade papanicolaou smear abnormalities.
Lytwyn A; Gafni A; Sellors JW; Goeree R; Randazzo J; Mahony JB; Daya D
J Low Genit Tract Dis; 1998 Oct; 2(4):213-20. PubMed ID: 25950215
[TBL] [Abstract][Full Text] [Related]
15. Evolution of the evidence-based Papanicolaou smear.
Mashburn J
J Midwifery Womens Health; 2001; 46(3):181-9. PubMed ID: 11480750
[TBL] [Abstract][Full Text] [Related]
16. The penurious Pap smear: will we ever see payment reflect costs?
Spires SE
Diagn Cytopathol; 1998 Aug; 19(2):81-3. PubMed ID: 9702480
[No Abstract] [Full Text] [Related]
17. Method comparison between Munich II and III nomenclature for Pap smear samples.
Cirkel C; Barop C; Beyer DA
J Turk Ger Gynecol Assoc; 2015; 16(4):203-7. PubMed ID: 26692769
[TBL] [Abstract][Full Text] [Related]
18. Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions.
Arbyn M; Roelens J; Simoens C; Buntinx F; Paraskevaidis E; Martin-Hirsch PP; Prendiville WJ
Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD008054. PubMed ID: 23543559
[TBL] [Abstract][Full Text] [Related]
19. An economic analysis of human papillomavirus triage for the management of women with atypical and abnormal Pap smear results in Germany.
Sheriff SK; Petry KU; Ikenberg H; Crouse G; Mazonson PD; Santas CC
Eur J Health Econ; 2007 Jun; 8(2):153-60. PubMed ID: 17308921
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
